Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta, Bhaskar; Elagouz, Mohammed; Sivaprasad, Sobha

doi:10.1038/eye.2009.201

Cited by 24 publications

(16 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14 Similar reports exist of outcomes of bevacizumab treatment in eyes with CNV secondary to non-AMD causes. 15 The use of intravitreal ranibizumab for the treatment of AS-related CNV has been reported to be more effective when compared with previous reports of laser photocoagulation or PDT, with most eyes demonstrating a stabilisation or improvement in visual acuity. However, most of these studies are limited to single case reports, small numbers of patients or have limited/short follow-up.…”

Section: Introductionmentioning

confidence: 78%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

Aims To assess the medium to long-term efficacy and safety of intravitreal ranibizumab for the treatment of choroidal neovascularisation (CNV) secondary to angioid streaks (AS). Methods A total of 12 eyes of nine patients treated with intravitreal ranibizumab (0.5 mg in 0.05 ml) for CNV secondary to AS were retrospectively identified. Efficacy of treatment was determined by changes in best-corrected LogMAR visual acuity (BCVA) and optical coherence tomography. Changes with respect to baseline BCVA were defined as improved or reduced with a gain or loss of more than 10 letters, respectively, or stable if remaining within 10 letters. Results Over a mean follow-up of 21.75 months (range: 1-54), patients received mean 5.75 (range: 2-15) intravitreal ranibizumab injections per affected eye. BCVA improved in three eyes (25%), stabilised in eight eyes (66.67%), and deteriorated in one eye (8.33%). There was no significant change in central retinal thickness (CRT) over the follow-up period (P ¼ 0.1072). No drug-related systemic side effects were recorded. Conclusion The long-term treatment of CNV secondary to AS with intravitreal ranibizumab showed a stabilisation in CRT and an improvement or stabilisation of BCVA. The absence of systemic side effects was reassuring. Further long-term prospective studies are required to validate these findings.

show abstract

Section: Introductionmentioning

confidence: 78%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

show abstract

“…Being the most common cause of CNV in young individuals in many countries, the prevalence was 62% of CNV in patients aged 50 years or less in one series 13. Although, similar in pathogenesis, non-AMD CNV generally responds better when compared with neovascular AMD 5. While myopic CNV is historically thought to only occur in eyes with pathological myopia, it is now recognised that myopic CNV can occur at any degree of myopia and in eyes without typical myopic degenerative funds changes 14 15.…”

Section: Discussionmentioning

confidence: 96%

Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group

Chhablani

Paulose

Lasave³

et al. 2017

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The etiology is still not well understood; however, the common occurrence of phenotypically similar AS among various systemic diseases, such as Paget’s disease, Ehlers–Danlos syndrome, and various blood dyscrasias (sickle cell disease and beta-thalassemia),1,5–7 suggests a common molecular mechanism encompassing antimineralization pathways 1,8. Possible candidates include mutations in ABCC6 gene transporter protein (multidrug resistance-associated protein 6), which is generally accepted to induce Pseudoxanthoma elasticum (PXE), the systemic disease with the highest association with AS, with an incidence ranging from 59% to 87% depending on whether the diagnosis is made clinically or with skin biopsy 1,4,8…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up of patients with choroidal neovascularization due to angioid streaks

Martínez-Serrano

Rodríguez-Reyes²,

Guerrero-Naranjo³

et al. 2016

OPTH

View full text Add to dashboard Cite

BackgroundThe following case series describes the long-term anatomical and functional outcome of a group of seven patients with choroidal neovascularization (CNV), secondary to angioid streaks (AS), who were treated with antiangiogenic drugs in a pro re nata (PRN) regimen. After the 4-year mark, visual acuity tends to return to pretreatment level. Treatment delays and lack of awareness and self-referral by the patients are believed to be the cause of the PRN regimen failure.PurposeTo assess the long-term outcomes (>4 years) of patients with CNV due to AS treated with a PRN regimen of antiangiogenic.MethodsThis was a retrospective, case series, single-center study. We reviewed the electronic medical records from patients with CNV due to AS. From each record, we noted general demographic data and relevant medical history; clinical presentation, changes in best-corrected visual acuity (BCVA) over time, optical coherent tomography parameters, treatment and retreatment details, and systemic associations. Changes in BCVA and central macular thickness were assessed with a Wilcoxon two-sample test, with an alpha value of ≤0.05 for statistical significance.ResultsThe mean follow-up time was 53.8±26.8 months. BCVA at baseline was: 1.001±0.62 logMAR; at the end of follow-up: 0.996±0.56 logMAR (P=0.9). Central macular thickness at baseline was: 360.85±173.82 μm; at the end of follow-up: 323.85±100.34 μm (P=0.6). Mean number of intravitreal angiogenic drugs: 6±4.16 injections (range 4–15). Mean time between injections was 3.8±2.7 months (range 1.9–5.8 months).ConclusionDespite initial anatomical and functional improvement, patients at the end of the follow-up had no visual improvement after a pro re nata regimen of antiangiogenic drugs. The amount of retreatments, number of recurrences, and time between intravitreal injections were similar to previous reports with shorter follow-up.

show abstract

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Cited by 24 publications

References 83 publications

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group

Long-term follow-up of patients with choroidal neovascularization due to angioid streaks

Contact Info

Product

Resources

About